Cargando…

A prospective Phase II study for the efficacy of radiotherapy in combination with zoledronic acid in treating painful bone metastases from gastrointestinal cancers

We investigated the efficacy of combined radiotherapy (RT) and zoledronic acid in treating painful bone metastases from gastrointestinal cancers. Sixty patients were prospectively enrolled between November 2014 and July 2016. The most common primary cancer type was hepatocellular carcinoma (HCC, n =...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Jinhyun, Lee, Eun Jung, Yang, Seung Hyun, Im, Yoo Ri, Seong, Jinsil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Regular Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430247/ https://www.ncbi.nlm.nih.gov/pubmed/30445597 http://dx.doi.org/10.1093/jrr/rry092

Ejemplares similares

Cryoablation combined with zoledronic acid in comparison with cryoablation and zoledronic acid alone in the treatment of painful bone metastases
por: LI, FENQIANG, et al.
Publicado: (2014)

Role of radiotherapy for pancreatobiliary neuroendocrine tumors
por: Lee, Jeongshim, et al.
Publicado: (2013)

Predictive Factors of Palliative Radiotherapy Response and Survival in Patients with Spinal Metastases from Hepatocellular Carcinoma
por: Choi, Chihwan, et al.
Publicado: (2015)

Effects of zoledronic acid and ibandronate in the treatment of cancer pain in rats with lung cancer combined with bone metastases
por: Wang, Gengshen, et al.
Publicado: (2018)

Phase II Study of Concurrent Capecitabine and External Beam Radiotherapy for Pain Control of Bone Metastases of Breast Cancer Origin
por: Kundel, Yulia, et al.
Publicado: (2013)

High dose and compartmental target volume may improve patient outcome after radiotherapy for pelvic bone metastases from hepatocellular carcinoma
por: Kim, Taehyung, et al.
Publicado: (2016)

Stereotactic radiotherapy using the CyberKnife is effective for local control of bone metastases from differentiated thyroid cancer
por: Ishigaki, Takayuki, et al.
Publicado: (2019)

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer
por: Terwogt, J M M, et al.
Publicado: (1999)

Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases
por: Quattrocchi, Carlo C., et al.
Publicado: (2012)

Pain REduction with bone metastases STereotactic radiotherapy (PREST): A phase III randomized multicentric trial
por: Cellini, Francesco, et al.
Publicado: (2019)

Challenge and Hope in Radiotherapy of Hepatocellular Carcinoma
por: Seong, Jinsil
Publicado: (2009)

The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer
por: Hadji, Peyman, et al.
Publicado: (2012)

Use of palliative radiotherapy in brain and bone metastases (VARA II study)
por: Expósito, Jose, et al.
Publicado: (2012)

Risk factors for severe gastrointestinal toxicity in patients receiving palliative radiotherapy for metastatic bone tumors: association with the use of molecular-targeted agents
por: Murakami, Yuji, et al.
Publicado: (2020)

Comparison of Single Versus Multifraction Radiotherapy in Palliation of Painful Bone Metastases
por: Nongkynrih, Anthialisha, et al.
Publicado: (2018)

Prophylactic corticosteroid to prevent pain flare in bone metastases treated by radiotherapy
por: Viani, Gustavo Arruda, et al.
Publicado: (2021)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
por: Jagdev, S P, et al.
Publicado: (2001)

Markers of bone turnover for the management of patients with bone metastases from prostate cancer
por: Garnero, P, et al.
Publicado: (2000)

Significant pain relief with loading dose zoledronic acid in bone metastases is only seen in patients with elevated initial serum C telopeptide (CTX)
por: Dekoninck, J, et al.
Publicado: (2011)

Adjuvant Zoledronic Acid in High‐Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial
por: Lipplaa, Astrid, et al.
Publicado: (2019)

A phase I/II trial of intraoperative breast radiotherapy in an Asian population: 10-year results with critical evaluation
por: Kawamura, Mariko, et al.
Publicado: (2020)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Rader, Michael, et al.
Publicado: (2012)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Xie, Jipan, et al.
Publicado: (2011)

Clinical outcomes of gastrointestinal brain metastases treated with radiotherapy
por: Sanghvi, Samrat M., et al.
Publicado: (2017)

Phase I dose-escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma
por: Kim, Jun Won, et al.
Publicado: (2016)

The effect of zoledronate during bone healing
por: Matos, Marcos Almeida, et al.
Publicado: (2010)

After radiotherapy, do bone metastases from gastrointestinal cancers show response rates similar to those of bone metastases from other primary cancers?
por: Hird, A., et al.
Publicado: (2008)

Strategic application of radiotherapy for hepatocellular carcinoma
por: Choi, Seo Hee, et al.
Publicado: (2018)

Electrochemotherapy in the Treatment of Bone Metastases: A Phase II Trial
por: Bianchi, Giuseppe, et al.
Publicado: (2016)

Recurrent Metastasized Parathyroid Carcinoma—Long‐Term Remission After Combined Treatments With Surgery, Radiotherapy, Cinacalcet, Zoledronic Acid, and Temozolomide
por: Storvall, Sara, et al.
Publicado: (2018)

Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy
por: Cha, Hyejung, et al.
Publicado: (2017)

Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases
por: Lam, Marnix G. E. H., et al.
Publicado: (2007)

Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report
por: Tokumaru, Yoshihisa, et al.
Publicado: (2019)

Phase II study of compensator-based non-coplanar intensity-modulated radiotherapy for Stage I non–small-cell lung cancer
por: Itonaga, Tomohiro, et al.
Publicado: (2019)

The Optimal Selection of Radiotherapy Treatment for Hepatocellular Carcinoma
por: Lee, Ik Jae, et al.
Publicado: (2012)

Evaluation of zoledronate for the treatment of canine stage III osteosarcoma: A phase II study
por: Smith, Ashley A., et al.
Publicado: (2022)

Establishment of a Disease-Specific Graded Prognostic Assessment for Hepatocellular Carcinoma Patients with Spinal Metastasis
por: Rim, Chai Hong, et al.
Publicado: (2017)

Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases – an evidence-based practice guideline
por: Wu, Jackson Sai-Yiu, et al.
Publicado: (2004)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases
por: Generali, D, et al.
Publicado: (2008)

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer
por: Hilton, J.F., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6bapv5s363s3jcm1c10q66sc2b